Obesity drug has no competitors on unexploited market, says Novo Nordisk

Executive Vice President cannot see any drug currently on the market that can compete with Novo Nordisk's recently approved Wegovy – but the company is still keeping its foot on the gas and launching quickly.

Photo: Stine Tidsvilde

It isn't pressure from competitors that is making Novo Nordisk aim for "the fastest launch after approval ever" for its new drug Wegovy, which was approved by the FDA on Friday.

According to Camilla Sylvest, Executive Vice President (EVP) for Commercial Strategy and Corporate Affairs, it is hard to find other drugs that can compete with Wegovy on the obesity market.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs